PTHS (Pelthos Therapeutics) Total Operating Expense: $60.35 Mil (TTM As of Mar. 2026)


PTHS Pelthos Therapeutics Inc PTHS
8 GF Score
Price $27.55
! 5 Warning Signs
View Full Analysis

What is Pelthos Therapeutics Total Operating Expense?

Pelthos Therapeutics PTHS -5.10% 8 Total Operating Expense is $60.35 Mil as of Mar. 2026. GuruFocus rates PTHS with a GF Score™ of 8/100. The stock has 5 warning signs investors should review.

Pelthos Therapeutics's Total Operating Expense for the three months ended in Mar. 2026 was $22.32 Mil. Pelthos Therapeutics's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $60.35 Mil.

Pelthos Therapeutics Total Operating Expense Related Terms

Pelthos Therapeutics Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Pelthos Therapeutics's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pelthos Therapeutics Total Operating Expense Chart

Pelthos Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial 0.84 2.32 6.86 7.57 39.86

Pelthos Therapeutics Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.83 3.23 17.79 17.00 22.32
PTHS
8GF Score
Pelthos Therapeutics Inc PTHS
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pelthos Therapeutics Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $60.35 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of $60.35 Mil mean?
Pelthos Therapeutics (PTHS) has a Total Operating Expense of $60.35 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Pelthos Therapeutics and its competitors.
Is Pelthos Therapeutics' Total Operating Expense too high?
Pelthos Therapeutics' current Total Operating Expense is $60.35 Mil. Overall, Pelthos Therapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Pelthos Therapeutics' Total Operating Expense compare to CGTX and BDTX?
Pelthos Therapeutics' Total Operating Expense of $60.35 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Pelthos Therapeutics and its competitors. Pelthos Therapeutics's current Total Operating Expense is $60.35 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pelthos Therapeutics stock overvalued right now?
Pelthos Therapeutics (PTHS) has a current Total Operating Expense of $60.35 Mil. The current Total Operating Expense is $60.35 Mil. Pelthos Therapeutics' overall GF Score™ is 8/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Pelthos Therapeutics (PTHS), the current Total Operating Expense is $60.35 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pelthos Therapeutics Business Description

Address 4020 Stirrup Creek Drive, Suite 110, Durham, NC, USA, 27703
Pelthos Therapeutics Inc is a biopharmaceutical company committed to commercializing safe and efficacious therapeutic products to help patients with unmet treatment burdens. The Company currently has three U.S. Food and Drug Administration (FDA) approved products in its commercial portfolio, in various stages of commercialization, including ZELSUVMITM, XEPI, and XEGLYZE. The company operates in two reporting segments: the sale, promotion, and commercialization of approved commercial products, the Commercial Operations segment, and research and development activities related to developing a novel and proprietary class of NaV blockers that target the body's peripheral nervous system; and supportive activities to expand the NITRICIL nitric oxide-based technology.
8GF Score

Get the complete analysis for PTHS

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$27.55
Price